Replies to post #18972 on The Rising Influence of Rising Affluence

[DewDiligence]

Investors are apparently expecting a hit to drug/biotech companies in the wake of the White House’s rescinding the proposal to ban drug rebates:

https://www.wsj.com/articles/insurer-relief-could-come-at-pharmas-expense-11562857155

For instance, MRK ($78.82 as I’m typing) is down 8% on the week.

[DewDiligence]

MRK 2Q19 results—Keytruda sales +63% YoY in constant currency.

2019 non-GAAP EPS guidance raised to $4.84-4.94 (from old range of $4.67-4.79). The midpoint of the new range represents 13% growth relative to 2018.

PR:
https://s21.q4cdn.com/488056881/files/doc_financials/2019/Q2/Merck-News-Release-07-30-19-Merck-Announces-Second-Quarter-2019-Financial-Results.pdf

CC slides:
https://s21.q4cdn.com/488056881/files/doc_financials/2019/Q2/Q219-Earnings-Deck_MRK.pdf